These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

184 related items for PubMed ID: 9652847

  • 21. Phase I trial of carboplatin, paclitaxel, etoposide, and cyclophosphamide with granulocyte colony stimulating factor as first-line therapy for patients with advanced epithelial ovarian cancer.
    Tung N, Berkowitz R, Matulonis U, Quartulli M, Seiden M, Kim Y, Niloff J, Cannistra SA.
    Gynecol Oncol; 2000 May; 77(2):271-7. PubMed ID: 10785477
    [Abstract] [Full Text] [Related]

  • 22. XM02, the first biosimilar G-CSF, is safe and effective in reducing the duration of severe neutropenia and incidence of febrile neutropenia in patients with small cell or non-small cell lung cancer receiving platinum-based chemotherapy.
    Gatzemeier U, Ciuleanu T, Dediu M, Ganea-Motan E, Lubenau H, Del Giglio A.
    J Thorac Oncol; 2009 Jun; 4(6):736-40. PubMed ID: 19404210
    [Abstract] [Full Text] [Related]

  • 23. Prospective and randomized comparison of early versus delayed prophylactic administration of granulocyte colony-stimulating factor (filgrastim) in children with cancer.
    Rahiala J, Perkkiö M, Riikonen P.
    Med Pediatr Oncol; 1999 May; 32(5):326-30. PubMed ID: 10219332
    [Abstract] [Full Text] [Related]

  • 24. Phase I trial of high-dose mitoxantrone plus cyclophosphamide and filgrastim in patients with advanced breast carcinoma.
    Sparano JA, Robert N, Silverman P, Lazarus H, Malik U, Venkatraj U, Sarta C.
    J Clin Oncol; 1996 Sep; 14(9):2576-83. PubMed ID: 8823338
    [Abstract] [Full Text] [Related]

  • 25. Open-label, randomized study of pegfilgrastim vs. daily filgrastim as an adjunct to chemotherapy in elderly patients with non-Hodgkin's lymphoma.
    Grigg A, Solal-Celigny P, Hoskin P, Taylor K, McMillan A, Forstpointner R, Bacon P, Renwick J, Hiddemann W, International Study Group.
    Leuk Lymphoma; 2003 Sep; 44(9):1503-8. PubMed ID: 14565651
    [Abstract] [Full Text] [Related]

  • 26. Beneficial impact of peripheral blood progenitor cells in patients with metastatic breast cancer treated with high-dose chemotherapy plus granulocyte-macrophage colony-stimulating factor. A randomized trial.
    Kritz A, Crown JP, Motzer RJ, Reich LM, Heller G, Moore MP, Hamilton N, Yao TJ, Heelan RT, Schneider JG.
    Cancer; 1993 Apr 15; 71(8):2515-21. PubMed ID: 8095854
    [Abstract] [Full Text] [Related]

  • 27. Intensive sequential chemotherapy with repeated blood stem-cell support for untreated poor-prognosis non-Hodgkin's lymphoma.
    Stoppa AM, Bouabdallah R, Chabannon C, Novakovitch G, Vey N, Camerlo J, Blaise D, Xerri L, Resbeut M, Di Stefano D, Bardou VJ, Gastaut JA, Maraninchi D.
    J Clin Oncol; 1997 May 15; 15(5):1722-9. PubMed ID: 9164178
    [Abstract] [Full Text] [Related]

  • 28. Colony-stimulating factors for the management of neutropenia in cancer patients.
    Dale DC.
    Drugs; 2002 May 15; 62 Suppl 1():1-15. PubMed ID: 12479591
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Safety and efficacy of pegfilgrastim compared to granulocyte colony stimulating factor (G-CSF) supporting a dose-intensive, rapidly cycling anti-metabolite containing chemotherapy regimen (Hyper-CVAD) for lymphoid malignancy.
    Lane SW, Crawford J, Kenealy M, Cull G, Seymour JF, Prince HM, Marlton P, Gill D, Mollee PN.
    Leuk Lymphoma; 2006 Sep 15; 47(9):1813-7. PubMed ID: 17064993
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Secondary prophylactic G-CSF (filgrastim) administration in chemotherapy of stage I and II Hodgkin's lymphoma with ABVD.
    Rueda A, Sevilla I, Gumà J, Ribelles N, Miramón J, De Las Nieves MA, Márquez A, Alba E.
    Leuk Lymphoma; 2001 Apr 15; 41(3-4):353-8. PubMed ID: 11378548
    [Abstract] [Full Text] [Related]

  • 34. Simultaneous dose escalation and schedule intensification of carboplatin-based chemotherapy using peripheral blood progenitor cells and filgrastim: a phase I trial.
    Fennelly D, Wasserheit C, Schneider J, Hakes T, Reich L, Curtin J, Yao TJ, Markman M, Norton L, Crown J.
    Cancer Res; 1994 Dec 01; 54(23):6137-42. PubMed ID: 7525055
    [Abstract] [Full Text] [Related]

  • 35. Increasing chemotherapy dose density and intensity: phase I trials in non-small cell lung cancer and non-Hodgkin's lymphoma.
    Blayney DW, McGuire BW, Cruickshank SE, Johnson DH.
    Oncologist; 2005 Feb 01; 10(2):138-49. PubMed ID: 15709216
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Peripheral-blood stem-cell collections after paclitaxel, cyclophosphamide, and recombinant human granulocyte colony-stimulating factor in patients with breast and ovarian cancer.
    Demirer T, Rowley S, Buckner CD, Appelbaum FR, Lilleby K, Storb R, Schiffman K, Bensinger WI.
    J Clin Oncol; 1995 Jul 01; 13(7):1714-9. PubMed ID: 7541450
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. [Clinical Investigation of the Effects of Filgrastim BS1 on Neutropenia Following Oral Cancer Chemotherapy (TPF Therapy)].
    Uchiyama K, Yamada M, Tamate S, Iwasaki K, Mitomo K, Nakayama S.
    Gan To Kagaku Ryoho; 2015 Sep 01; 42(9):1073-6. PubMed ID: 26469162
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.